Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 06-Mar-2018

Epigenetic medicine for Alzheimer


After years of successful drug discovery for various university Dr Hasib Salah-Uddin has decided to partner with a seasoned CEO and develop a medicine for the most challenging disease of our times: Alzheimer. A disease that will impact 16 Million Americans by 2050, 1 in 3 seniors.

Main pharmaceuticals companies such as Eli Lilly and Merck just announced to have terminated efforts for solving Alzheimer's disease, dismantled their labs and created venture capital fund to invest in innovative firms..

Additional Questions

Who is your customer?

Pharmaceutical companies involved in clinical development such as: Eli Lilly and Merck. These companies prefer to acquire innovation.

What problem does this idea/product solve or what market need does it serve?

It reveres neurodegeneration and cognitive impairment, which are indicators of Alzheimer, Lewy Body Dementia ( trying to connect with FAU Prof James Galvin).

What attributes will make this idea/product successful? Why do you believe that those features will create success?

Our innovative approach uses a mutli-target approach to a complex multi-factorial disease i.e. Alzheimer, using a single small molecule (> 500 MW that is CNS penetrant) with an Epigenetic mechanism of action. Epigenetics (the science of gene expression) has been the technology used to solve in-met medical needs in the last few years. We have a patented technology based on targeting disease biology in Alzheimer disease using Epigenetics. Dr Hasib has already made a new drug discovery with Epigenetic.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

Dr Hasib Salah-Uddin is the world leader on Epigenetic drug discovery nad has published a well reviewed scientific article on the topic: https://miami.pure.elsevier.com/en/publications/m344-promotes-nonamyloidogenic-amyloid-precursor-protein-processi Starting from our provisional patent on the new compound targeting Alzheimer using an Epigenetic approach, we will engage an in Silico drug design SME (Subject Matter Expert). Once we have identified the optimal compound we will do chemical synthesis of the designed compound. In Vitro Target validation, efficacy testing, in vitro cell model In Vivo behavioral testing for cognition improvements, APP/PS1 transenic mouse model for Alzheimer disease. In parallel we will be looking to reverse the hallmarks of AD such amloynd plaques and tangles observed in the brain of those animals. Dr Hasib Uddin has worked for many years at UM (Univeristy of Miami) on